These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 27671499

  • 1. Tetrahydropyrazolo[4,3-c]pyridine derivatives as potent and peripherally selective cannabinoid-1 (CB1) receptor inverse agonists.
    Zhu B, Matthews JM, Xia M, Black S, Chen C, Hou C, Liang Y, Tang Y, Macielag MJ.
    Bioorg Med Chem Lett; 2016 Nov 15; 26(22):5597-5601. PubMed ID: 27671499
    [Abstract] [Full Text] [Related]

  • 2. Differential effects of cannabinoid CB1 inverse agonists and antagonists on impulsivity in male Sprague Dawley rats: identification of a possibly clinically relevant vulnerability involving the serotonin 5HT1A receptor.
    McLaughlin PJ, Jagielo-Miller JE, Plyler ES, Schutte KK, Vemuri VK, Makriyannis A.
    Psychopharmacology (Berl); 2017 Mar 15; 234(6):1029-1043. PubMed ID: 28144708
    [Abstract] [Full Text] [Related]

  • 3. Characterization of a novel, brain-penetrating CB1 receptor inverse agonist: metabolic profile in diet-induced obese models and aspects of central activity.
    Jacobson LH, Commerford SR, Gerber SP, Chen YA, Dardik B, Chaperon F, Schwartzkopf C, Nguyen-Tran V, Hollenbeck T, McNamara P, He X, Liu H, Seidel HM, Jaton AL, Gromada J, Teixeira S.
    Naunyn Schmiedebergs Arch Pharmacol; 2011 Dec 15; 384(6):565-81. PubMed ID: 21947251
    [Abstract] [Full Text] [Related]

  • 4. Tetrahydroindazole derivatives as potent and peripherally selective cannabinoid-1 (CB1) receptor inverse agonists.
    Matthews JM, McNally JJ, Connolly PJ, Xia M, Zhu B, Black S, Chen C, Hou C, Liang Y, Tang Y, Macielag MJ.
    Bioorg Med Chem Lett; 2016 Nov 01; 26(21):5346-5349. PubMed ID: 27671496
    [Abstract] [Full Text] [Related]

  • 5. Pyrazole antagonists of the CB1 receptor with reduced brain penetration.
    Fulp A, Zhang Y, Bortoff K, Seltzman H, Snyder R, Wiethe R, Amato G, Maitra R.
    Bioorg Med Chem; 2016 Mar 01; 24(5):1063-70. PubMed ID: 26827137
    [Abstract] [Full Text] [Related]

  • 6. Second generation CB1 receptor blockers and other inhibitors of peripheral endocannabinoid overactivity and the rationale of their use against metabolic disorders.
    Silvestri C, Di Marzo V.
    Expert Opin Investig Drugs; 2012 Sep 01; 21(9):1309-22. PubMed ID: 22780328
    [Abstract] [Full Text] [Related]

  • 7. Controlled downregulation of the cannabinoid CB1 receptor provides a promising approach for the treatment of obesity and obesity-derived type 2 diabetes.
    Lu D, Dopart R, Kendall DA.
    Cell Stress Chaperones; 2016 Jan 01; 21(1):1-7. PubMed ID: 26498013
    [Abstract] [Full Text] [Related]

  • 8. Peripherally restricted CB1 receptor blockers.
    Chorvat RJ.
    Bioorg Med Chem Lett; 2013 Sep 01; 23(17):4751-60. PubMed ID: 23902803
    [Abstract] [Full Text] [Related]

  • 9. Prospective therapeutic agents for obesity: molecular modification approaches of centrally and peripherally acting selective cannabinoid 1 receptor antagonists.
    Sharma MK, Murumkar PR, Kanhed AM, Giridhar R, Yadav MR.
    Eur J Med Chem; 2014 May 22; 79():298-339. PubMed ID: 24747288
    [Abstract] [Full Text] [Related]

  • 10. Fluorine-18 isotope labeling for positron emission tomography imaging. Direct evidence for DBPR211 as a peripherally restricted CB1 inverse agonist.
    Chang CP, Huang HL, Huang JK, Hung MS, Wu CH, Song JS, Lee CJ, Yu CS, Shia KS.
    Bioorg Med Chem; 2019 Jan 01; 27(1):216-223. PubMed ID: 30528163
    [Abstract] [Full Text] [Related]

  • 11. Contrasting effects of different cannabinoid receptor ligands on mouse ingestive behaviour.
    Grey J, Terry P, Higgs S.
    Behav Pharmacol; 2012 Sep 01; 23(5-6):551-9. PubMed ID: 22772336
    [Abstract] [Full Text] [Related]

  • 12. Functionalized 6-(Piperidin-1-yl)-8,9-Diphenyl Purines as Peripherally Restricted Inverse Agonists of the CB1 Receptor.
    Amato G, Manke A, Wiethe R, Vasukuttan V, Snyder R, Yueh YL, Decker A, Runyon S, Maitra R.
    J Med Chem; 2019 Jul 11; 62(13):6330-6345. PubMed ID: 31185168
    [Abstract] [Full Text] [Related]

  • 13. Efficacy in diet-induced obese mice of the hepatotropic, peripheral cannabinoid 1 receptor inverse agonist TM38837.
    Cooper ME, Nørregaard PK, Högberg T, Andersson G, Receveur JM, Linget JM, Elling CE.
    Br J Pharmacol; 2024 Oct 11; 181(20):3926-3943. PubMed ID: 38886096
    [Abstract] [Full Text] [Related]

  • 14. Diphenyl purine derivatives as peripherally selective cannabinoid receptor 1 antagonists.
    Fulp A, Bortoff K, Zhang Y, Seltzman H, Mathews J, Snyder R, Fennell T, Maitra R.
    J Med Chem; 2012 Nov 26; 55(22):10022-32. PubMed ID: 23098108
    [Abstract] [Full Text] [Related]

  • 15. Overcoming the Psychiatric Side Effects of the Cannabinoid CB1 Receptor Antagonists: Current Approaches for Therapeutics Development.
    Nguyen T, Thomas BF, Zhang Y.
    Curr Top Med Chem; 2019 Nov 26; 19(16):1418-1435. PubMed ID: 31284863
    [Abstract] [Full Text] [Related]

  • 16. Novel effects of the cannabinoid inverse agonist AM 251 on parameters related to metabolic syndrome in obese Zucker rats.
    Merroun I, Sánchez-González C, Martínez R, López-Chaves C, Porres JM, Aranda P, Llopis J, Galisteo M, Zarzuelo A, Errami M, López-Jurado M.
    Metabolism; 2013 Nov 26; 62(11):1641-50. PubMed ID: 23932644
    [Abstract] [Full Text] [Related]

  • 17. Peripheral selectivity of the novel cannabinoid receptor antagonist TM38837 in healthy subjects.
    Klumpers LE, Fridberg M, de Kam ML, Little PB, Jensen NO, Kleinloog HD, Elling CE, van Gerven JM.
    Br J Clin Pharmacol; 2013 Dec 26; 76(6):846-57. PubMed ID: 23601084
    [Abstract] [Full Text] [Related]

  • 18. NESS038C6, a novel selective CB1 antagonist agent with anti-obesity activity and improved molecular profile.
    Mastinu A, Pira M, Pani L, Pinna GA, Lazzari P.
    Behav Brain Res; 2012 Oct 01; 234(2):192-204. PubMed ID: 22771813
    [Abstract] [Full Text] [Related]

  • 19. Reports of the death of CB1 antagonists have been greatly exaggerated: recent preclinical findings predict improved safety in the treatment of obesity.
    McLaughlin PJ.
    Behav Pharmacol; 2012 Sep 01; 23(5-6):537-50. PubMed ID: 22743603
    [Abstract] [Full Text] [Related]

  • 20. Synthesis, Biological Evaluation, and Molecular Modeling Studies of 3,4-Diarylpyrazoline Series of Compounds as Potent, Nonbrain Penetrant Antagonists of Cannabinoid-1 (CB1R) Receptor with Reduced Lipophilicity.
    Iyer MR, Cinar R, Wood CM, Zawatsky CN, Coffey NJ, Kim KA, Liu Z, Katz A, Abdalla J, Hassan SA, Lee YS.
    J Med Chem; 2022 Feb 10; 65(3):2374-2387. PubMed ID: 35084860
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.